Zotatifin

About eFFECTOR Therapeutics

eFFECTOR Therapeutics was founded to exploit dysregulated protein synthesis as a new therapeutic strategy in oncology. Its mission was to develop selective translation regulator inhibitors (STRIs) targeting the eIF4F complex, advancing two primary candidates, zotatifin and tomivosertib, into clinical trials for various solid tumors. The company's strategy was to move beyond targeting single mutations to disrupt the broader 'translationome' driving tumor growth and therapy resistance. Despite achieving key clinical milestones and raising significant capital as a public entity, eFFECTOR ultimately failed to secure further funding or partnerships, leading to its dissolution.

Therapeutic Areas